Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Regulation of natural killer cell function.

Andrew P Makrigiannis1, Stephen K Anderson

  • 1Institut de Recherches Cliniques de Montreal, Laboratory of Molecular Immunology, Montreal, Quebec Canada. makriga@ircm.qc.ca

Cancer Biology & Therapy
|December 23, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lineage-specific chromatin poising enforced by ETS-IRF composite elements determines the divergent interferon responses of plasmacytoid dendritic cells and epithelial cells.

bioRxiv : the preprint server for biology·2026
Same author

Nitric oxide-driven Warburg reprogramming at the NOS2-COX2 axis: An integrative engine of cancer hallmarks.

Redox biology·2026
Same author

NOS2 and COX2 impact the spatial landscape of CD8<sup>+</sup> T cells in ER-breast cancer, providing novel mechanistic insight that drives tumor progression and poor survival.

Redox biology·2026
Same author

Peptide-adaptive NK cell memory in the absence of functional TCR genes.

ImmunoHorizons·2026
Same author

Cell fate determination is associated with changes in competing transcriptional units in the human <i>GATA1</i> and <i>GATA2</i> lineage-determining transcription factors.

bioRxiv : the preprint server for biology·2025
Same author

Elevated tumor NOS2/COX2 promotes immunosuppressive phenotypes associated with poor survival in ER- breast cancer.

JCI insight·2025

Natural killer (NK) cells are crucial for fighting viral infections and cancer. Understanding the diversity of NK cell receptors and their ligands is key to harnessing the innate immune system for disease treatment.

Area of Science:

  • Immunology
  • Innate Immunity
  • Cancer Biology

Background:

  • Natural killer (NK) cells are vital for immune surveillance against viral infections and cancer.
  • Downregulation of MHC class I molecules by tumors and infected cells can evade NK cell detection.
  • Genetic diversity in NK cell receptors (e.g., Ly49, KIR, NKG2A/CD94) influences individual immune responses.

Purpose of the Study:

  • To explore the significance of NK cell receptor gene diversity in immunity to pathogens and cancer.
  • To highlight the role of activating NK cell receptors (e.g., Ly49H, NKG2D) and their ligands (e.g., m157, Rae1).
  • To underscore the clinical relevance of MHC class I receptor diversity in preventing leukemia relapse post-bone marrow transplant.

Main Methods:

  • Review of current evidence on NK cell function and receptor-ligand interactions.

Related Experiment Videos

  • Analysis of genetic diversity in NK cell receptor genes across different individuals and mouse strains.
  • Examination of clinical data related to bone marrow transplantation and leukemia relapse.

    • Main Results:

    • NK cell deficiency leads to increased susceptibility to viral infections and cancer.
    • Specific activating NK cell receptors recognize viral and tumor ligands, mediating immune responses.
    • MHC class I receptor diversity plays a beneficial role in preventing post-transplant leukemic relapse.

    Conclusions:

    • Further research into NK cell receptors and tumor ligands can optimize innate immune system exploitation.
    • Understanding NK cell receptor diversity is crucial for developing novel therapeutic strategies against infections and malignancies.
    • Targeting NK cell pathways offers potential for improved treatment of leukemia and other cancers.